Trialbee Announces Release of HIVE
Trialbee has announced the release of HIVE, a smart data science application applied on Real World Data aiming to enhance targeting and precision in performance-driven patient recruitment for global clinical trials.
“Traditional patient recruitment has limited access to patients and takes a long time to accomplish. Digital advertising for clinical trials, to supplement the pool of patients available to investigators, often results in large burdensome screening activities for the sites only to result in a few additional patients to enroll. Trialbee HIVE uses a smart modeling technique and expands the pool of potential clinical trial participants and then narrows down the pool to only the most relevant candidates matching the study criteria,” said Lollo Eriksson, Chief Strategy Officer at Trialbee.
For more information, click here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
